The Defense Logistics Agency (DLA) awarded a $7,256.28 firm fixed price delivery order to Dakota Drug, Inc., a self-certified small disadvantaged business based in Anoka, Minnesota, for the supply of Mounjaro 7.5 mg/0.5 mL pen injections. The delivery order, issued on July 17, 2025, with an ultimate completion date of July 18, 2025, represents an unrestricted award with no set-aside designation. This delivery order falls under Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 31, 2025, which was established under the DLA's ECAT Generation V Program solicitation SPE2DH-21-R-0002.
Dakota Drug, Inc. serves as a critical pharmaceutical and medical supplies vendor to the Defense Logistics Agency, specializing in medications and healthcare equipment that support U.S. Armed Forces medical operations. The company's contract portfolio demonstrates extensive experience delivering diabetes management products, respiratory medications, pain management drugs, cardiovascular treatments, and vaccines to military healthcare facilities. This delivery order for Mounjaro, a diabetes management medication, exemplifies the vendor's ongoing role in supplying essential pharmaceutical products through the DLA's streamlined procurement vehicle, ensuring reliable access to critical medications for defense healthcare operations.
Generated 12/16/25, 3:00 AM